内幕人士在Insmed股票中出售了3M多美元, Insiders sold over $3M in Insmed stock amid earnings miss and market concerns.

2026年1月6日至8日,包括CEO William Lewis、CFO Sara Bonstein 和 COO Roger Adsett 在内的多个独立执行官在不同的交易中总共出售了21 000多股股份,产生了300多万美元的收益。 On January 6–8, 2026, multiple Insmed executives, including CEO William Lewis, CFO Sara Bonstein, and COO Roger Adsett, sold a combined total of over 21,000 shares in separate transactions, generating more than $3 million in proceeds. 以每股173.33美元至175.07美元的价格出售SEC表格4所申报的股票,1月9日,公司股票交易量上升,1月9日跌至170.27美元。 The sales, disclosed in SEC Form 4 filings, occurred at prices between $173.33 and $175.07 per share, with the company’s stock trading down to $170.27 on January 9 amid elevated volume. 内部活动紧随第三季度盈利报告表现不一，每股亏损1.75美元，低于预期，尽管收入同比增长52.4%。 The insider activity follows a mixed Q3 earnings report showing a $1.75 per share loss, below estimates, though revenue rose 52.4% year-over-year. Pomerantz LLP对潜在投资者索赔的调查和另一个内幕人士的大宗整笔销售增加了市场不确定性。 A Pomerantz LLP investigation into potential investor claims and a large block sale by another insider have added market uncertainty. 尽管“机动购买”分析师达成了共识,而且目标价格为205.64美元,投资者仍然对内幕持续出售感到关切。 Despite a "Moderate Buy" analyst consensus and a $205.64 target price, investor concern persists over the sustained insider selling.